Novavax (NVAX) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts NVAX Hot Sheet
Price: $9.35 --0%
Revenue Growth %: -78.2%
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: -78.2%
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $14 million versus the consensus estimate of $9.9 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- JPMorgan Starts Zensho Holdings (7550:JP) at Overweight
- AbbVie updates 2026 EPS guidance after $291M IPR&D charge
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
